Abstract 14P
Background
Homologous recombination deficiency (HRD) is a clinically-proven indicator of sensitivity against platinum-based chemotherapy and PARP inhibitors in various malignancies, including ovarian cancers. Until now, HRD prediction has been carried out by detecting the deleterious mutations of the BRCA1 or BRCA2 gene or measuring genomic scar, i.e., scarHRD. However, the scarHRD method has limitations in applying tumors without matched germline data. Investigating HRD-specific transcriptomic signatures is one of the tangible approaches to predicting HRD in tumor-only samples. Although several RNA-seq-based HRD prediction algorithms have been developed, they support mainly cohort-wise classification regarding HRD status yet do not provide an equivalent value to scarHRD. The transformation into scarHRD from transcriptomic data would be highly valuable for clinical application and research use.
Methods
Here, we developed an algorithm of transcriptome-based HRD analysis, i.e., expHRD. The prediction model was established using the elastic net in TCGA-pan cancer training set. HRD geneset for applying expHRD calculation using single-sample geneset enrichment analysis was derived by bootstrap technique.
Results
expHRD is a clinically applicable RNA-seq-based HRD prediction platform in tumor-only samples. In clinic, expHRD can provide supportive information for predicting platinum or PARP inhibitor responses by providing predicted scarHRD score. We could extract the expHRD to analyze the inter-cohort evaluation, HRD-associated gene expression profile, mutations, or tumor types in samples without matched germline data, such as cryopreserved or formalin-fixed tissues, cell lines, or organoids.
Conclusions
Developing a targeted transcriptomic panel for calculating expHRD would be a cost-effective approach to linking our platform with the clinic.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
136P - Molecular correlates of drug response to guide therapy in TNBC
Presenter: Nathan Merrill
Session: Cocktail & Poster Display session
Resources:
Abstract
137P - Event-free survival prediction using lncRNAs in pediatric B-cell acute lymphoblastic leukemia
Presenter: Unai Illarregi
Session: Cocktail & Poster Display session
Resources:
Abstract
138P - Exome sequencing analysis for the identification of actionable mutations related to neoadjuvant chemotherapy response in locally advanced breast cancer
Presenter: Ximena López
Session: Cocktail & Poster Display session
Resources:
Abstract
139P - Genomic prognostic and potential theragnostic factors in anal squamous cell carcinoma treated with abdominoperineal resection
Presenter: Abderaouf Hamza
Session: Cocktail & Poster Display session
Resources:
Abstract
144P - Correlation of EZH2 expression and response to chemoradiotherapy in patients with locally advanced inoperable oral cavity and oropharyngeal squamous cell cancers
Presenter: Soel Ahmed
Session: Cocktail & Poster Display session
Resources:
Abstract
140P - Predictive value of DNA damage response and repair gene alterations and neoscore for neoadjuvant immunotherapies in non-small cell lung cancer
Presenter: Fei Feng
Session: Cocktail & Poster Display session
Resources:
Abstract
141P - Immune-related epigenomic and transcriptomic signatures to predict immunotherapy response in NSCLC
Presenter: María Gallardo-Gómez
Session: Cocktail & Poster Display session
Resources:
Abstract
142P - Role and impact of hypoxia-inducible factor 1-alpha on survival rates in pancreatic cancer: A systematic review and meta-analysis
Presenter: Muhammed Elfaituri
Session: Cocktail & Poster Display session
Resources:
Abstract
143P - Genomic characterization and outcomes of patients with primary sclerosing cholangitis-related cholangiocarcinoma
Presenter: Jaime Haro Silerio
Session: Cocktail & Poster Display session
Resources:
Abstract
145P - Identification of next generation sequencing (NGS)-based genomic signature predicting resistance to immunotherapy (IO) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC): A single-center cohort study
Presenter: Antonio Vitale
Session: Cocktail & Poster Display session
Resources:
Abstract